Impact of a Diagnosis or Lack of a Diagnosis of Endometriosis Via a Saliva Test on Pain Catastrophizing, Quality of Life, Symptoms of Anxiety and Depression, and Treatment Adherence (ENDETECT)
This non-interventional study aims to assess the impact of an endometriosis diagnosis obtained through a salivary test (Ziwig Endotest®) on pain-related cognitions, quality of life, mood, and treatment adherence, comparingthese outcomes with those of individuals who underwent the same salivary test but received a negative result and were therefore not diagnosed with endometriosis.
Participation in this study will contribute to advancing research in the field of endometriosis diagnosis and multidisciplinary management by expanding current knowledge of diagnostic protocols and their impact on pain, quality of life, treatment adherence, and potential psychiatric comorbidities. The investigators hope to enhance understanding of endometriosis and pelvic pain symptomatology in order to develop new therapeutic strategies, including psychological interventions or integrated psychological care, that better address the needs and specific characteristics of patients whether or not they receive a diagnosis of endometriosis.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Celine CLAIRET-LESPINASSE
- Número de teléfono: +33 3204441145
- Correo electrónico: celine.clairet@chu-lille.fr
Copia de seguridad de contactos de estudio
- Nombre: DRS. Promotion
- Número de teléfono: +33 3204441145
- Correo electrónico: drs.promotion@chu-lille.fr
Ubicaciones de estudio
-
-
-
Lille, Francia
- CHU de Lille
-
Contacto:
- Celine CLAIRET-LESPINASSE
- Número de teléfono: +33320444145
- Correo electrónico: celine.clairet@chu-lille.fr
-
Contacto:
- Chrydtele RUBOD DIT GUILLET, Pr
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Patients referred for suspected endometriosis, with negative imaging findings and for whom an endotest has been indicated.
Descripción
Inclusion Criteria:
- Patients eligible for an endotest as part of the innovation package at Jeanne de Flandre Hospital
- Patients between 18 to 43 years old
- Understand and can communicate in French
- Having received medical images that do not allow the diagnosis of endometriosis
- Presenting with symptoms suggestive of endometriosis
- Giving oral non-opposition to participe in the study
- Beneficiary of health insurance coverage
- Having normal visual and auditory acuity or corrected to normal levels
Exclusion Criteria:
- Minors, adults under guardianship, under judicial protection, and persons deprived of liberty
- Refusal to participate after receiving clear and fair information about the study
- Sensory, visual or auditory inability to participate in the study
- Personal history of neurological disorders or current neurological disorder
- Consumtion of toxic substances other than tobacco and alcohol.
- Personal history of psychiatric disorders or current psychiatric disorders other than anxiety, depressive, or trauma- and stress-related disorders
- Use of psychotropic medications
- Pregnant or breastfeeding women
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: CASE_ONLY
- Perspectivas temporales: PROSPECTIVE
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Changes in pain catastrophizing 1 month after being informed of the results of the saliva test among patients diagnosed with endometriosis and among patients not diagnosed with endometriosis.
Periodo de tiempo: 1 month + 3 weeks
|
Change in the Pain Catastrophizing Scale score between baseline and 1 month after the announcement of the salivary test results. Use : Questionnaire Pain Catastrophizing scale-13 items divided into three dimensions: "rumination," "magnification," and "helplessness"-scored on a scale of 0 to 4-maximum total score of 52 points. |
1 month + 3 weeks
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Changes 1 month after the consultation during which the results of the salivary test for pain catastrophizing were announced, based on the diagnosis of endometriosis.
Periodo de tiempo: 6 months + 3 weeks
|
Change from baseline to 1 month after the announcement of the salivary test results in the Pain Catastrophizing Scale score. Use : Questionnaire Pain Catastrophizing scale-13 items divided into three dimensions: "rumination," "magnification," and "helplessness"-scored on a scale of 0 to 4-maximum total score of 52 points. |
6 months + 3 weeks
|
|
Changes at 1 month and 6 months after the consultation during which the saliva test results were announced, based on whether endometriosis was diagnosed: • Quality of life • Anxiety and depressive symptoms • Treatment adherence
Periodo de tiempo: 6 months + 3 weeks
|
Change from baseline to 1 month after the results were announced, and from baseline to 6 months after the results were announced. Use:
|
6 months + 3 weeks
|
|
Changes at 6 months following the consultation during which the results of the salivary test for pain catastrophizing were reported, based on the diagnosis of endometriosis.
Periodo de tiempo: 6 months + 3 weeks
|
To compare the change in pain catastrophizing at 6 months following the consultation disclosing the salivary test results, between patients diagnosed with endometriosis and those not diagnosed with endometriosis. Use : Questionnaire Pain Catastrophizing scale-13 items divided into three dimensions: "rumination," "magnification," and "helplessness"-scored on a scale of 0 to 4-maximum total score of 52 points. |
6 months + 3 weeks
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades urogenitales
- Enfermedades Genitales
- Desordenes mentales
- Procesos Patológicos
- Enfermedades urogenitales femeninas
- Enfermedades urogenitales femeninas y complicaciones del embarazo
- Síntomas de comportamiento
- Enfermedades Genitales Femeninas
- Condiciones Patológicas, Signos y Síntomas
- Comportamiento
- Desórdenes de ansiedad
- Depresión
- Enfermedad
- Endometriosis
Otros números de identificación del estudio
Otros números de identificación del estudio
- 2025_0266
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .